Boehringer Mannheim Gmbh

Protein Design Labs, Inc.

Boehringer Mannehim Gmbh

Ulrich Martin

Stephan Fischer

Anne Stern

Ulrich Kohnert

Christos Tsaklakidis

Alfred Mertens

Wolfgang Von Der Saal

Rainer Rudolph

Hans-Willi Krell

Nicholas F Landolfi

Richard Engh

Chung Nan Chang

Erwin Boehm

Reinhard Koenig

Reinhard Konig

Silvia Konetschny-Rapp

Reinhard K&ouml;nig

Jens-Peter Hoelck

Discussed are therapeutic approaches to the treatment of thrombolic conditions. The therapies use thrombolytically active proteins which inhibit reocclusion in the subject. The proteins are administered in two or more boli.

Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins

The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.

Use of the protease domain of human plasminogen activator for the

The invention relates to monoclonal antibodies, humanized monoclonal antibodies and functional derivatives thereof specific for the platelet-derived growth factor receptor .beta.. Methods of use of the antibody, particularly in ameliorating restenosis, are also provided.

Monoclonal antibodies specific for the platelet derived growth factor

Compound of formula (I) are disclosed ##STR1## as well as optically active isomers or pharmacologically acceptable salts thereof. The compounds are useful active ingredients in pharmaceutical compositions, and methods of treating osteoporosis, inflammation or diseases which are due to thromboembolic events. Compounds of formula (II) are also disclosed ##STR2## which are useful as starting compounds for preparing compounds of formula (I).

Amidinopyrroline derivatives, processes for their production and

The use of various thrombolytically active proteins in therapy is disclosed. The proteins are markedly superior to wild type t-PA in their pharmacokinetic, pharmacodynamic, and safety profiles.

Method for treating thromboembolic conditions using thrombolytically

The invention relates to the use of thromboembolic proteins. These contain, as their only structural portion effecting thrombolytic activity, the protease domain of human tissue type plasminogen activator. These derivatives show reduced side effects, such as a reduction in bleeding while. demonstrating remarkable in vivo efficacy. The effect is surprising, given their in vitro properties.

Discussed are therapeutic approaches to the treatment of thrombolic conditions. The therapies use thrombolytically active proteins which function by, e.g., inhibiting reocclusion in the subject. The proteins are administered in two or more boli.

Method for treating thromboembolic conditions via the use of multiple

The invention involves thromboembolically effective compositions and therapeutic methods. Thrombolytically active proteins are combined with anticoagulants, as long as the anticoagulant is not heparin. The anticoagulant is administered in an intravenous bolus form, while the thrombolytically active protein may be administered via intravenous bolus, or intravenous infusion.

Combinations of thrombolytically active proteins and non-heparin

Method for treating thromboembolic conditions by inhibiting reocclusion

Thrombolytically active non-glycosylated protein

The present invention is concerned with the use of compounds of the general formula: ##STR1## wherein R.sub.1 is a phenyl radical of the general formula: ##STR2## or R.sub.1 is a 5 or 6 membered heterocycle or when X is a valency bond R.sub.1 is also H, OH, mercapto, amino, alkyl, alkenyl, alkynyl, haloalkyl, alkylthio, formylaminoalkyl, pyridylcarbonylamino, cycloalkyl, or cycloalkenyl, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl or hydroxyalkyl of claim 1 or 2 for the preparation of pharmaceutical compositions with an erythrocyte aggregation inhibition action useful, for example, in states of shock or circulatory disturbance.

Growing community of inventors

Mannheim, Germany

Ulrich Martin